116 related articles for article (PubMed ID: 11318431)
1. Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide.
Safgren SL; Reid JM; Rios R; Ames MM
J Chromatogr B Biomed Sci Appl; 2001 Apr; 754(1):91-6. PubMed ID: 11318431
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of dacarbazine (DTIC) in pregnancy.
Kantrowitz-Gordon I; Hays K; Kayode O; Kumar AR; Kaplan HG; Reid JM; Safgren SL; Ames MM; Easterling TR; Hebert MF
Cancer Chemother Pharmacol; 2018 Mar; 81(3):455-460. PubMed ID: 29305638
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma.
Rajkumar SV; Reid JM; Novotny PJ; Safgren SL; Scheithauer BW; Johnson PS; Nair S; Morton RF; Hatfield AK; Krook JE; Ames MM; Buckner JC;
J Neurooncol; 2000 Sep; 49(3):255-61. PubMed ID: 11212905
[TBL] [Abstract][Full Text] [Related]
4. 5-(3-Hydroxymethyl-3-methyl-1-triazeno imidazole-4-carboxamide is a metabolite of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DIC, DTIC NSC-45388).
Kolar GF; Maurer M; Wildschütte M
Cancer Lett; 1980 Sep; 10(3):235-41. PubMed ID: 7427920
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
Tsang LL; Quarterman CP; Gescher A; Slack JA
Cancer Chemother Pharmacol; 1991; 27(5):342-6. PubMed ID: 1998993
[TBL] [Abstract][Full Text] [Related]
6. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1.
Reid JM; Kuffel MJ; Miller JK; Rios R; Ames MM
Clin Cancer Res; 1999 Aug; 5(8):2192-7. PubMed ID: 10473105
[TBL] [Abstract][Full Text] [Related]
7. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.
Kim HK; Lin CC; Parker D; Veals J; Lim J; Likhari P; Statkevich P; Marco A; Nomeir AA
J Chromatogr B Biomed Sci Appl; 1997 Dec; 703(1-2):225-33. PubMed ID: 9448080
[TBL] [Abstract][Full Text] [Related]
8. Reversed-phase high-performance liquid chromatography of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide and metabolites.
Tate PS; Briele HA
J Chromatogr; 1986 Jan; 374(2):421-4. PubMed ID: 3958101
[No Abstract] [Full Text] [Related]
9. An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma.
Chowdhury SK; Laudicina D; Blumenkrantz N; Wirth M; Alton KB
J Pharm Biomed Anal; 1999 Apr; 19(5):659-68. PubMed ID: 10698531
[TBL] [Abstract][Full Text] [Related]
10. Validated hydrophilic interaction LC-MS/MS method for simultaneous quantification of dacarbazine and 5-amino-4-imidazole-carboxamide in human plasma.
Liu Y; Zhang W; Yang Y
Talanta; 2008 Oct; 77(1):412-21. PubMed ID: 18804654
[TBL] [Abstract][Full Text] [Related]
11. Carcinogenicity of the antineoplastic agent, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, and its metabolites in rats.
Beal DD; Skibba JL; Croft WA; Cohen SM; Bryan GT
J Natl Cancer Inst; 1975 Apr; 54(4):951-7. PubMed ID: 1127724
[TBL] [Abstract][Full Text] [Related]
12. Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide and its metabolites on Novikoff hepatoma cells.
Beal DD; Skibba JL; Whitnable KK; Bryan GT
Cancer Res; 1976 Aug; 36(8):2827-31. PubMed ID: 179708
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of dacarbazine, its photolytic degradation product, 2-azahypoxanthine, and the metabolite 5-aminoimidazole-4-carboxamide in plasma and urine by high-pressure liquid chromatography.
Fiore D; Jackson AJ; Didolkar MS; Dandu VR
Antimicrob Agents Chemother; 1985 Jun; 27(6):977-9. PubMed ID: 4026274
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide.
Lunn JM; Harris AL
Br J Cancer; 1988 Jan; 57(1):54-8. PubMed ID: 2831926
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
Reid JM; Stevens DC; Rubin J; Ames MM
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2393-8. PubMed ID: 9815639
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic effects of the methylating agent 5-(3-methyl-1-triazeno) imidazole-4-carboxamide in human melanoma cells.
Hayward IP; Parsons PG
Aust J Exp Biol Med Sci; 1984 Oct; 62 ( Pt 5)():597-606. PubMed ID: 6534346
[TBL] [Abstract][Full Text] [Related]
17. In vitro mutagenic activity of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in eukaryotic and prokaryotic cells.
Bartoli-Klugmann F; Pani B; Babudri N; Montibragadin C; Tamaro M; Venturini S
Carcinogenesis; 1982; 3(5):467-71. PubMed ID: 7046979
[TBL] [Abstract][Full Text] [Related]
18. [Determination of dacarbazine in the urine of mice with melanoma by high performance liquid chromatography].
Yue Y; Zhou B; Ai J; Feng S
Se Pu; 2020 Nov; 38(11):1302-1307. PubMed ID: 34213101
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of high-dose DTIC.
Buesa JM; Urréchaga E
Cancer Chemother Pharmacol; 1991; 28(6):475-9. PubMed ID: 1934251
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
